HCAT — Insider Trading Activity
One insider at HCAT put personal money into the stock on the open market this window, led by the CEO, with nobody selling.
What this means for HCAT
HCAT is not showing a cluster buy or a step-change versus its own baseline, so what the window amounts to is a single insider acting alone. Who is buying. The most credible buyer in this window is the company’s CEO ($100K–$500K), growing their stake by 2%. Overall credibility score: 34/100 (Low).
By the numbers. One insider filed 1 open-market purchase at HCAT over the window, 59,000 shares in all at an average of $1.79 a share, most recently on September 14, 2026. No insider sold HCAT stock on the open market in that period.
How we read these filings — which transaction codes count, how the cluster and credibility thresholds are set, and what the signals have and haven’t predicted — is written up in the insider trading methodology.
HCAT insider filings, one by one
The single Form 4 filing from the last 90 days, with share count, dollar amount and date.
Other tickers with the same signal
Companies of a comparable size whose Form 4 filings tripped the same insider buying flag as HCAT in this window.
- GBCI insider trading — 1 buyer, credibility 19/100
- BMR insider trading — 1 buyer, credibility 34/100
- BROS insider trading — 1 buyer, credibility 21/100
- INDV insider trading — 1 buyer, credibility 30/100
- BMI insider trading — 1 buyer, credibility 26/100